January 2025 - Cingulate completed its final FDA-required study, a food effect study utilizing a single 50-mg dose of ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.

Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 - consisting of the Business Report, ...

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in ...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Topline data from registration-intent DENALI Part 2 ...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 - consisting of the Business Report ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of potential new medicine, all based on our ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Makary, a prominent voice on U.S. health care practices throughout his career, spent 22 years at Hopkins Medicine ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort.